- Home
- FHN vs ROIV Comparison
FHN vs ROIV Comparison
Compare FHN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- ROIV
- Stock Information
- Founded
- FHN 1864
- ROIV 2014
- Country
- FHN United States
- ROIV United Kingdom
- Employees
- FHN N/A
- ROIV N/A
- Industry
- FHN Major Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- ROIV Health Care
- Exchange
- FHN Nasdaq
- ROIV Nasdaq
- Market Cap
- FHN 8.9B
- ROIV 8.4B
- IPO Year
- FHN N/A
- ROIV N/A
- Fundamental
- Price
- FHN $15.33
- ROIV $12.30
- Analyst Decision
- FHN Buy
- ROIV Strong Buy
- Analyst Count
- FHN 13
- ROIV 10
- Target Price
- FHN $17.31
- ROIV $17.33
- AVG Volume (30 Days)
- FHN 3.9M
- ROIV 4.2M
- Earning Date
- FHN 10-16-2024
- ROIV 08-08-2024
- Dividend Yield
- FHN 3.91%
- ROIV N/A
- EPS Growth
- FHN N/A
- ROIV N/A
- EPS
- FHN 1.21
- ROIV 5.65
- Revenue
- FHN $2,947,000,000.00
- ROIV $158,303,000.00
- Revenue This Year
- FHN N/A
- ROIV $45.51
- Revenue Next Year
- FHN $3.34
- ROIV $42.29
- P/E Ratio
- FHN $12.69
- ROIV $2.18
- Revenue Growth
- FHN N/A
- ROIV 101.44
- 52 Week Low
- FHN $10.08
- ROIV $8.25
- 52 Week High
- FHN $17.46
- ROIV $13.24
- Technical
- Relative Strength Index (RSI)
- FHN 40.47
- ROIV 65.79
- Support Level
- FHN $16.07
- ROIV $11.50
- Resistance Level
- FHN $16.76
- ROIV $12.60
- Average True Range (ATR)
- FHN 0.36
- ROIV 0.35
- MACD
- FHN -0.05
- ROIV 0.04
- Stochastic Oscillator
- FHN 2.39
- ROIV 79.19
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The regional bank is responsible for roughly 65% of its revenue, while capital markets make a 25% contribution. The remainder is split between the firm's non-strategic (wind-down) and corporate operations. First Horizon concentrates on offering a variety of banking products mainly in its home state, where it has the second- largest deposit franchise with a 13% deposit market share.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.